Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Paolo Ascierto

Paolo Ascierto

MD
National Tumor Institute Fondazione G. Pascale, Naples, Italy
Novel druggable targets for keratinocyte skin cancer 3:48
Novel druggable targets for keratinocyte skin cancer
Paolo Ascierto • 19 Apr 2021
SECOMBIT: sequencing of targeted agents/immunomodulatory Abs in metastatic BRAFV600-mutated melanoma 4:46
SECOMBIT: sequencing of targeted agents/immunomodulatory Abs in metastatic BRAFV600-mutated melanoma
Paolo Ascierto • 19 Sep 2020
Melanoma musings: Dr Ascierto’s trial updates from ESMO 5:39
Melanoma musings: Dr Ascierto’s trial updates from ESMO
Paolo Ascierto • 1 Oct 2019
Who are the long-term responders to immuno and targeted therapy in melanoma? 3:24
Who are the long-term responders to immuno and targeted therapy in melanoma?
Paolo Ascierto • 28 Sep 2019
Encouraging phase 3 CheckMate 238 data: adjuvant nivolumab in resected stage III/IV melanoma 2:56
Encouraging phase 3 CheckMate 238 data: adjuvant nivolumab in resected stage III/IV melanoma
Paolo Ascierto • 29 Sep 2019
Melanoma: combining or sequencing targeted agents and immunotherapy? 3:26
Melanoma: combining or sequencing targeted agents and immunotherapy?
Paolo Ascierto • 3 Jun 2019
Stage IV melanoma: Frontline options 1:18
Stage IV melanoma: Frontline options
Paolo Ascierto • 3 Jun 2019
Melanoma Bridge 2018: key issues 2:25
Melanoma Bridge 2018: key issues
Paolo Ascierto • 2 Jun 2019
IMO-2125 plus ipilimumab for anti-PD-1 refractory melanoma: ILLUMINATE-301 1:36
IMO-2125 plus ipilimumab for anti-PD-1 refractory melanoma: ILLUMINATE-301
Paolo Ascierto
BRAF-positive melanoma: what’s new? 2:18
BRAF-positive melanoma: what’s new?
Paolo Ascierto • 19 Oct 2018
Dabrafenib/trametinib/pembrolizumab for advanced melanoma: update from KEYNOTE-022 4:24
Dabrafenib/trametinib/pembrolizumab for advanced melanoma: update from KEYNOTE-022
Paolo Ascierto • 19 Oct 2018
MEK inhibitors for melanoma: new combination approved 2:02
MEK inhibitors for melanoma: new combination approved
Paolo Ascierto • 19 Oct 2018
Emerging melanoma therapeutics: IDO1, LAG-3 & HDAC inhibitors 2:49
Emerging melanoma therapeutics: IDO1, LAG-3 & HDAC inhibitors
Paolo Ascierto • 1 Jun 2018
Novel combinations for melanoma: PD-1 inhibitor triplet regimens 2:06
Novel combinations for melanoma: PD-1 inhibitor triplet regimens
Paolo Ascierto • 1 Jun 2018
Melanoma advancements: immunotherapy in the adjuvant setting 1:15
Melanoma advancements: immunotherapy in the adjuvant setting
Paolo Ascierto • 1 Jun 2018
Novel agent combination therapies in melanoma: talimogene laherparepvec, PV-10 & IMO-2125 4:06
Novel agent combination therapies in melanoma: talimogene laherparepvec, PV-10 & IMO-2125
Paolo Ascierto • 1 Jun 2018
The content of VJOncology is intended for healthcare professionals